Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Thumbnail
View/Open
Publication Date
2017-10
ICR Author
Author
Seddon, B
Strauss, SJ
Whelan, J
Leahy, M
Woll, PJ
Cowie, F
Rothermundt, C
Wood, Z
Benson, C
Ali, N
Marples, M
Veal, GJ
Jamieson, D
Küver, K
Tirabosco, R
Forsyth, S
Nash, S
Dehbi, H-M
Beare, S
Type
Journal Article
Metadata
Show full item record
URL
https://repository.icr.ac.uk/handle/internal/1450
Collections
Version of record
Language
en
License start date
2017-10
Citation
The Lancet Oncology, 2017, 18 (10), pp. 1397 - 1410
Publisher
Elsevier BV